Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26088305 | 1.00 | AHR (0.34) | AHR | |
| SCHEMBL26088868 | 1.00 | AHR (0.34) | AHR | |
| SCHEMBL26088483 | 0.84 | ALDH1A1 (0.34) | AHR | |
| SCHEMBL26419161 | 0.81 | ALDH1A1 (0.47) | — | |
| SCHEMBL26088630 | 0.81 | ALDH1A1 (0.47) | — | |
| SCHEMBL26419131 | 0.76 | RAB9A (0.54) | AHR | |
| SCHEMBL26419141 | 0.76 | RAB9A (0.54) | AHR | |
| SCHEMBL26088179 | 0.76 | RAB9A (0.54) | AHR | |
| SCHEMBL26089228 | 0.74 | DRD2 (0.31) | — | |
| SCHEMBL26086552 | 0.71 | AHR (0.38) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4402126-A1 | AHR AGONISTS | Eli Lilly and Company (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118215654-A | AHR agonists | 伊莱利利公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
| WO-2023039278-A1 | AHR AGONISTS | ELI LILLY AND COMPANY (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037322-B2 | AHR agonists | AHR, ARNT, RORC | AHR 1/4885 |
| US-20230127797-A1 | AHR AGONISTS | AHR, ARNT, RORC | AHR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.